Literature DB >> 18567922

Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis.

J M Anderson1, D W Hampton, R Patani, G Pryce, R A Crowther, R Reynolds, R J M Franklin, G Giovannoni, D A S Compston, D Baker, M G Spillantini, S Chandran.   

Abstract

The pathological correlate of clinical disability and progression in multiple sclerosis is neuronal and axonal loss; however, the underlying mechanisms are unknown. Abnormal phosphorylation of tau is a common feature of some neurodegenerative disorders, such as Alzheimer's disease. We investigated the presence of tau hyperphosphorylation and its relationship with neuronal and axonal loss in chronic experimental autoimmune encephalomyelitis (CEAE) and in brain samples from patients with secondary progressive multiple sclerosis. We report the novel finding of abnormal tau phosphorylation in CEAE. We further show that accumulation of insoluble tau is associated with both neuronal and axonal loss that correlates with progression from relapsing-remitting to chronic stages of EAE. Significantly, analysis of secondary progressive multiple sclerosis brain tissue also revealed abnormally phosphorylated tau and the formation of insoluble tau. Together, these observations provide the first evidence implicating abnormal tau in the neurodegenerative phase of tissue injury in experimental and human demyelinating disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18567922     DOI: 10.1093/brain/awn119

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  52 in total

1.  Autoimmune manifestations in the 3xTg-AD model of Alzheimer's disease.

Authors:  Monica Marchese; David Cowan; Elizabeth Head; Donglai Ma; Khalil Karimi; Vanessa Ashthorpe; Minesh Kapadia; Hui Zhao; Paulina Davis; Boris Sakic
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 2.  The role of environmental exposures in neurodegeneration and neurodegenerative diseases.

Authors:  Jason R Cannon; J Timothy Greenamyre
Journal:  Toxicol Sci       Date:  2011-09-13       Impact factor: 4.849

Review 3.  The utility of cerebrospinal fluid analysis in patients with multiple sclerosis.

Authors:  Martin Stangel; Sten Fredrikson; Edgar Meinl; Axel Petzold; Olaf Stüve; Hayrettin Tumani
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

4.  Inducible Expression of a Truncated Form of Tau in Oligodendrocytes Elicits Gait Abnormalities and a Decrease in Myelin: Implications for Selective CNS Degenerative Diseases.

Authors:  Patrizia LoPresti
Journal:  Neurochem Res       Date:  2015-09-22       Impact factor: 3.996

5.  Sphingosine Kinase 2 Potentiates Amyloid Deposition but Protects against Hippocampal Volume Loss and Demyelination in a Mouse Model of Alzheimer's Disease.

Authors:  Mona Lei; Jonathan D Teo; Huitong Song; Holly P McEwen; Jun Yup Lee; Timothy A Couttas; Thomas Duncan; Rose Chesworth; Josefine Bertz; Magdalena Przybyla; Janet Van Eersel; Benjamin Heng; Gilles J Guillemin; Lars M Ittner; Thomas Fath; Brett Garner; Arne Ittner; Tim Karl; Anthony S Don
Journal:  J Neurosci       Date:  2019-10-22       Impact factor: 6.167

6.  Evaluation of [(11)C]N-Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles.

Authors:  Xia Shao; Garrett M Carpenter; Timothy J Desmond; Phillip Sherman; Carole A Quesada; Maria Fawaz; Allen F Brooks; Michael R Kilbourn; Roger L Albin; Kirk A Frey; Peter J H Scott
Journal:  ACS Med Chem Lett       Date:  2012-09-25       Impact factor: 4.345

Review 7.  Nogo-A Antibodies for Progressive Multiple Sclerosis.

Authors:  Benjamin V Ineichen; Patricia S Plattner; Nicolas Good; Roland Martin; Michael Linnebank; Martin E Schwab
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

Review 8.  Targeting progressive neuroaxonal injury: lessons from multiple sclerosis.

Authors:  Amit Bar-Or; Peter Rieckmann; Anthony Traboulsee; V Wee Yong
Journal:  CNS Drugs       Date:  2011-09-01       Impact factor: 5.749

Review 9.  Pharmacological approaches to intervention in hypomyelinating and demyelinating white matter pathology.

Authors:  Li-Jin Chew; Cynthia A DeBoy
Journal:  Neuropharmacology       Date:  2015-06-24       Impact factor: 5.250

10.  Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy.

Authors:  Monica Javidnia; Michaeline L Hebron; Yue Xin; Nikolas G Kinney; Charbel E-H Moussa
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.